

Title (en)

OF AT USE OF AN ANTAGONIST COMPOUND OF AT LEAST ONE RECEPTOR SELECTED FROM A GROUP COMPRISING BETA-ADRENERGIC RECEPTORS, A AT1, 5-HT5 AND GALANIN RECEPTOR FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR TREATING ROSACEA

Title (de)

VERWENDUNG EINER ANTAGONISTISCHEN VERBINDUNG VON MINDESTEN EINEM REZEPTOR AUSGEWÄHLT AUS EINER GRUPPE VON BETA-ADRENERGEN REZEPTOREN, EINEM AT1, 5-HT5 UND GALANIN-REZEPTOR ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ROSACEA

Title (fr)

UTILISATION D'UN COMPOSE ANTAGONISTE D'AU MOINS UN RECEPTEUR CHOISI DANS LE GROUPE COMPRENANT LES RECEPTEURS BETA-ADRENERGIQUES, LE RECEPTEUR AT1, 5-HT5 ET DE LA GALANINE, POUR LA PREPARATION D'UNE COMPOSITION PHARMACEUTIQUE DESTINEE A TRAITER LA ROSACEE

Publication

EP 1722855 A1 20061122 (FR)

Application

EP 05729329 A 20050217

Priority

- FR 2005000367 W 20050217
- FR 0401715 A 20040220

Abstract (en)

[origin: FR2866567A1] Compounds (I) that are beta-adrenergic, AT1, 5-HT2, 5-HT5 or galanin receptor antagonists, other than metronidazole, are used to prepare pharmaceutical compositions for treating rosacea. ACTIVITY : Dermatological. MECHANISM OF ACTION : beta-Adrenergic receptor antagonist; AT1 receptor antagonist; 5-HT2 receptor antagonist; 5-HT5 receptor antagonist; Galanin receptor antagonist. Test details are described but no results for the compounds of the claims are given.

IPC 8 full level

A61P 17/10 (2006.01); **A61K 31/166** (2006.01); **A61K 31/167** (2006.01); **A61K 31/195** (2006.01); **A61K 31/196** (2006.01); **A61K 31/216** (2006.01); **A61K 31/404** (2006.01); **A61K 31/41** (2006.01); **A61K 31/416** (2006.01); **A61K 31/4164** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/496** (2006.01); **A61K 31/517** (2006.01); **A61K 31/519** (2006.01); **A61K 31/5377** (2006.01)

CPC (source: EP US)

A61K 31/166 (2013.01 - EP US); **A61K 31/167** (2013.01 - EP US); **A61K 31/195** (2013.01 - EP US); **A61K 31/196** (2013.01 - EP US); **A61K 31/216** (2013.01 - EP US); **A61K 31/404** (2013.01 - EP US); **A61K 31/41** (2013.01 - EP US); **A61K 31/416** (2013.01 - EP US); **A61K 31/4178** (2013.01 - EP US); **A61K 31/4184** (2013.01 - EP US); **A61K 31/4196** (2013.01 - EP US); **A61K 31/496** (2013.01 - EP US); **A61K 31/517** (2013.01 - EP US); **A61K 31/519** (2013.01 - EP US); **A61K 31/5377** (2013.01 - EP US); **A61P 17/00** (2017.12 - EP); **A61P 17/10** (2017.12 - EP)

Citation (search report)

See references of WO 2005089871A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

LV

DOCDB simple family (publication)

FR 2866567 A1 20050826; CA 2553208 A1 20050929; EP 1722855 A1 20061122; US 2007275978 A1 20071129; WO 2005089871 A1 20050929

DOCDB simple family (application)

FR 0401715 A 20040220; CA 2553208 A 20050217; EP 05729329 A 20050217; FR 2005000367 W 20050217; US 59007705 A 20050217